RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets. RINVOQ LQ is taken twice a day with or without food. RINVOQ LQ is available in a 1 mg/mL oral solution.

--AbbVie today announces that the U.S. Food and Drug Administration has approved RINVOQ ®, an oral therapy, for the treatment of adults with active non-radiographic axial spondyloarthritis with ...

– The co-primary endpoints of endoscopic response (visible reduction of intestinal lining damage) and clinical remission were achieved by significantly more patients treated with RINVOQ ...

Results from the maintenance study also showed that 57% and 68% of patients receiving upadacitinib 15mg or 30mg ... extended-release tablets in a 28-count bottle. Rinvoq is also approved for ...

AbbVie's (ABBV) JAK inhibitor, Rinvoq monotherapy achieves improvement in skin clearance and reduction in itch in significantly higher proportion of atopic dermatitis patients in a phase III study.

--AbbVie today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use recommended the approval of RINVOQ™, an oral, once daily selective and reversible JAK ...

Rinvoq showed long-term efficacy and safety up to 140 weeks in the treatment of ... 88.8% of patients treated with 15 mg and 90.3% treated with 30 mg achieved EASI 75 and 63.4% and 65 ...

The most commonly reported adverse reactions in AD trials (≥2% of patients) with RINVOQ 15 mg or 30 mg were upper respiratory tract infection, acne, herpes simplex, headache, blood CPK increased ...

AbbVie ABBV announced positive top-line results from a late-stage study, U-EXCEED, on Rinvoq (upadacitinib), a selective and reversible JAK inhibitor. AbbVie’s study enrolled patients with ...

NORTH CHICAGO, Ill., Oct. 21, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announces that the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib 15 mg, once daily), an ...

NORTH CHICAGO, Ill., April 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ ® (upadacitinib), 15 mg, once daily, for ...